Our team

Many Abliva employees are active in preclinical and clinical development, as well as a number of external consultants engaged on the company’s projects. The company possesses a high level of expertise. All employees are science graduates, with five holding PhDs in medical sciences. The company’s researchers are engaged in identifying segments with unmet medical needs, early basic research and clinical research towards approval of drug candidates.

Management team

Ellen K. Donnelly

CEO

Ellen K. Donnelly, born 1974, is a highly experienced and strategic drug development executive. She has held leading positions in both large and small pharma/biotech companies, including as CEO of Modus Therapeutics AB (Sweden), CEO of Souvien Therapeutics (US), CEO of the Epigenetics Division of Juvenescence (UK) and she has spent almost a decade at Pfizer, Inc. (US) in a variety of leadership positions. Ellen’s expertise includes business and clinical development strategies, as well as interacting with specialized investors, especially in the US. She also has experience in management consulting. Ellen has a Ph.D. in Pharmacology from Yale University.

No of shares: –

Catharina Jz. Johansson

Deputy CEO, CFO & VP Investor Relations

Catharina Jz Johansson, born 1967, possesses experience from work on medtech growth enterprises with multinational operations. Catharina Johansson holds a master’s degree in Business and Economics from Mid Sweden University. Her previous experience includes serving as interim CFO for medical device company Cellavision, which is listed on Nasdaq Stockholm, and Accounting Manager for Bong and Alfa Laval Europe. Employed since 2013.

No of shares: 100,000

Eskil Elmér

CSO & Vice President Discovery

Eskil Elmér, born 1970, is consultant physician and adjunct professor of basal and clinical neurophysiology at Lund University (Sweden) and group leader of the Mitochondrial Medicine lab at the department of Clinical Neurophysiology. Dr Elmér is patentee and co-founder of both Maas Biolab, LLC and Abliva AB (former NeuroVive Pharmaceutical AB), and CSO of Abliva, with overall charge of the company’s pre-clinical research. In addition, Eskil Elmér is a practising physician in the department of clinical neurophysiology at Skåne University Hospital in Lund, Sweden. Employed since 2000.

No of shares: 621,487 Privately owned (including family) and 17.09% of Maas Biolab, LLC which owns 2.1% of Abliva.

Magnus Hansson

CMO & VP Preclinical and Clinical Development

Magnus Hansson, born 1976, has extensive experience in the area of Mitochondrial Medicine. He has previously been serving as a Senior Scientist in NeuroVive since 2008 and as a consultant physician and associate professor in medical imaging and physiology at Skåne University Hospital, Sweden. Dr Hansson has overall charge of the company’s pre-clinical and clinical development programs. He holds a PhD in Experimental brain research from Lund University, Sweden and has authored more than 30 scientific publications and 10 patent applications. Employed since 2008.

No of shares: 559,639 (including family)

Additional members in core team

Matilda Hugerth

Director Clinical and Regulatory Affairs

Matilda Hugerth, born 1975, has during the past 20 years held various positions in the pharmaceutical industry including Lundbeck, UCB, and Novartis. Her experience includes all clinical phases in areas of regulatory, project management, clinical operations, clinical quality assurance, and medical affairs. She holds a master’s degree in Pharmaceutical Sciences from Uppsala University, Sweden, and is a registered pharmacist. Matilda is a member of the European Federation of GCP Audit working party, and is on the steering committee of Medicon Village´s regulatory affairs network in Lund, Sweden. Employed since 2016.

Alvar Grönberg

Director Preclinical Development

Alvar Grönberg, born 1955, has held various positions in the pharmaceutical industry including Pharmacia, Biovitrum and Pergamum since 30 years. His expertise and experience includes pre-clinical research and development as well as early clinical development. Alvar directs all Abliva’s preclinical activities. He holds a PhD in Tumor Immunology from Karolinska Institutet, Sweden and has authored more than 40 scientific publications and 4 patent applications. Employed since 2014.

Eleonor Åsander Frostner

Communications Officer/Lab Manager

Eleonor Åsander Frostner, born 1981, has ten years of experience in the area of mitochondrial physiology/medicine and research, serving as laboratory engineer and manager in the Mitochondrial Medicine lab at Lund University, Sweden, and Abliva. She holds a master’s degree in Biomedical Sciences from Lund University. Eleonor is part of Abliva’s Investor Relations team and manages the company’s external communications. Employed since 2011.

Key strategy consultants

Frank J. Sasinowski

M.S., M.P.H., J.D., New York, USA.

US Regulatory Consultant

Joined the FDA in 1983. 
He was key to implementing the Orphan Drug 
law and the Hatch-Waxman law. 

Has helped secure FDA approval for hundreds 
of new drugs, including more than 65 new molecular entities, many for serious and/or 
rare diseases.

Johan Bring

Senior Statistician at Statisticon AB, Uppsala/Stockholm, Sweden.

Statistics Consultant

Accomplished and innovative statistican who founded the company Statisticon in 1987.

Has since supported numerous pharma and biotech companies e.g. AstraZeneca with statistcal expertise.

Fredrik Nicklasson

MSci Pharm, PhD in Pharmaceutics from Uppsala University, Sweden.

CMC Consultant

Has worked as formulation specialist, line manager and project manager in the pharmaceutical CMC area of the pharma industry for over 13 years.

Projects with contractors in material characterization, product development and manufacturing of drug products.